PLK4 overexpression is observed in diffuse large B-cell lymphoma (DLBCL) and is associated with poor survival in patients receiving cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (oncovin), and prednisone (CHOP)-based treatment. The gene discussed is PLK4; the disease is diffuse large B-cell lymphoma.